Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | CASP3 | P42574 | 2/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21639432 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL25357928 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL31427181 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL18191950 | 1.00 | MDM4 (0.60) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL21639211 | 0.90 | MDM4 (0.58) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL21639208 | 0.90 | MDM4 (0.58) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL8895610 | 0.89 | MDM4 (0.62) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL242522 | 0.88 | KMT2A (0.51) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL242521 | 0.88 | KMT2A (0.51) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL30092486 | 0.88 | KMT2A (0.51) | MDM4TP53CASP3MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719381-A1 | LIGAND-POLAR DRUG CONJUGATES | Tripartite Therapeutics Inc. (TW) | 2026-04-08 | — | — | EP | disclosed |
| US-20250032635-A1 | LIGAND-POLAR DRUG CONJUGATES | TRIPARTITE THERAPEUTICS INC. (TW) | 2025-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032635-A1 | LIGAND-POLAR DRUG CONJUGATES | CD274, SELPLG, PDCD1LG2 | MDM4 3638/4885TP53 195/4885CASP3 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.